Is metastatic pancreatic cancer an untargetable malignancy?

doi:10.4251/wjgo.v8.i3.297

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9682)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

526

WORD

271

HTML

3852

Tables (1-3)

186

Sum=4835

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

462

Download

1286

Sum=1748

Publishing Process of This Article

Item

Count

Browse

1239

Download

1860

Sum=3099

Mar 15, 2016 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Mar 15, 2016; 8(3): 297-304
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.297

Table 2 Clinical trials in metastatic pancreatic cancer associating two targeted therapies to chemotherapeutical agents

Ref.	Regimen	Phase	PFS	OS
Van Cutsem et al[18]	Gemcitabine/erlotinib/bevacizumab Gemcitabine/erlotinib	III	4.6	7.1
Van Cutsem et al[18]	Gemcitabine/erlotinib/bevacizumab Gemcitabine/erlotinib	III	3.6	6.0
Philip et al[19]	Gemcitabine/erlotinib/cixutumumab Gemcitabine/erlotinib	I	3.6	7.0
Philip et al[19]	Gemcitabine/erlotinib/cixutumumab Gemcitabine/erlotinib	I	3.6	6.7
Watkins et al[20]	Gemcitabine/capecitabine/erlotinib/bevacizumab	I/II	8.4	12.6
NCT02450656 (ongoing trial)	Afatinib/selumetinib	II	NA	NA
NCT02450656 (ongoing trial)	Capecitabine	II	NA	NA

PFS: Progression free survival; OS: Overall survival; NA: Not available.

Citation: Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8(3): 297-304
URL: https://www.wjgnet.com/1948-5204/full/v8/i3/297.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.297